NCT02474641

Brief Summary

Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible. Investigators initiated this multicenter two-armed phase III prospective trial to analyse the non-inferiority of hypofractionation with simultaneous integrated boost in patients with early breast cancer in comparison to standard fractionation.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,324

participants targeted

Target at P75+ for not_applicable

Timeline
23mo left

Started Jun 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

88 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress85%
Jun 2015Mar 2028

First Submitted

Initial submission to the registry

June 4, 2015

Completed
12 days until next milestone

Study Start

First participant enrolled

June 16, 2015

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 18, 2015

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 8, 2019

Completed
9.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2028

Expected
Last Updated

March 21, 2024

Status Verified

March 1, 2024

Enrollment Period

3.6 years

First QC Date

June 4, 2015

Last Update Submit

March 19, 2024

Conditions

Keywords

Breast cancerHypofractionation with SIBNon-inferiorityadjuvant radiotherapy with simultaneous integrated boost

Outcome Measures

Primary Outcomes (1)

  • Progression free survival

    any local or regional recurrence or distant metastasis or death

    3 to 6 years

Secondary Outcomes (5)

  • Time to occurence of local recurrence

    3 to 6 years

  • Overall survival

    3 to 6 years

  • Safety and side effects (Number of Patients with Adverse Events)

    3 to 6 years

  • Acute and chronic toxicity (NCI-CTCAE)

    1 day, 7 days, end of radiation (last day of radiation and closing visite), 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months, 60 months, 66 months, 72 months

  • Cosmetic results (NCI-CTCAE)

    1 day, end of radiation (last day of radiation and closing visite), 3 months, 12 months, 24 months, 36 months, 48 months, 60 months, 72 months

Study Arms (2)

Standard radiation

ACTIVE COMPARATOR

Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially

Radiation: Standard Radiation

Hypofractionation with SIB

EXPERIMENTAL

Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed

Radiation: Hypofractionation with SIB

Interventions

Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially

Standard radiation

Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed

Hypofractionation with SIB

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Histopathologically confirmed breast cancer operated by breast conserving surgery with clear margins independently of further risk factors (positive or high-risk negative lymph node status, estrogen- or progesterone receptor status, Her-2/neu status uPA/PAI-1 criteria) and postoperative systemic therapy (chemotherapy, endocrine, antibody or bisphosphonate therapy were permitted when indicated)
  • Indication to adjuvant radiotherapy including boost radiotherapy
  • Clearly identified primary tumor region preferably by radiopaque clips
  • Primary wound healing after breast conserving therapy without signs of infection
  • Age ≥ 18 years
  • ECOG ≤ 2 Performance Status
  • Written informed consent
  • Compliance regarding treatment appointments and toxicity
  • Linguistic and cognitive ability to understand the questionnaires

You may not qualify if:

  • Patients operated by mastectomy
  • No indication for boost radiation (e.g. status after IORT)
  • double sided breast cancer
  • Resection margins positive for disease or insufficient identification of the boost volume
  • Indication for radiotherapy of the regional lymph nodes
  • History of prior breast or thoracic radiotherapy
  • Extended postoperative seroma at the beginning of radiotherapy
  • Previously administered radiotherapy not allowing the required dose
  • Pregnant or lactating patients and woman of child bearing potential, who lacked effective contraception
  • treatment history of other cancer or participation in another clinical trial testing radiotherapy or drugs within 4 weeks of the start of treatment.
  • Patients with serious, uncontrolled, physical or cerebrovascular disorders(e.g. myocardial infarction within the last 12 months) or neurologiy or psychiatric disorders thought to adversly affect treatment compliance

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (88)

Gesundheitszentrum St.Marien Gmbh und Klinik für Strahlentherapie

Amberg, 92224, Germany

Location

Medizinisches Versorgungszentrum Aue

Aue, 08280, Germany

Location

Helios Kliniken Bad Saarow Klinik für Radioonkologie

Bad Saarow, 15526, Germany

Location

HELIOS Klinikum Bad Saarow

Bad Saarow, 15526, Germany

Location

Strahlentherapie Klinikum Bayreuth

Bayreuth, 95445, Germany

Location

Medizinisches Versorgungs Zentrum Diagnostisch Therapeutisches Zentrum am Frankfurter Tor

Berlin, 10243, Germany

Location

Strahlentherapie in Moabit /Praxis für Strahlentherapie

Berlin, 10559, Germany

Location

Praxis für Radioonkologie und Strahlentherapie Berlin Südwest

Berlin, 12157, Germany

Location

Ambulantes Gesundheitszentrum der Dr. med Maria Sternemann Charte -Universitätsmedizin Berlin

Berlin, 12200, Germany

Location

Vivantes-Klinikum Berlin-Neukölln

Berlin, 12351, Germany

Location

HELIOS Klinikum Berlin-Buch, Strahlentherapeutische Klinik

Berlin, 13125, Germany

Location

Charite berlin (Virchow) Klinik für Strahlentherapie

Berlin, 13353, Germany

Location

DRK Kliniken Berlin: Zentrum für Strahlentherapie MVZ pro patiente Westend

Berlin, 14050, Germany

Location

MZV am HELIOS Klinikum Emil von Behring

Berlin, 14165, Germany

Location

Gemeinschaftspraxis und Belegabteilung für Strahlentherapie

Bocholt, 46399, Germany

Location

Ambulanz Bremen GMBH MVZ RadioOnkologie

Bremen, 28205, Germany

Location

Zentrum für Strahlentherapie undRadioonkologie

Bremen, 28239, Germany

Location

Krankenhaus Buchholz Abteilung für Strahlentherapie

Buchholz, 21244, Germany

Location

Strahlentherapie Coesfeld

Coesfeld, 48653, Germany

Location

Radiologie Strahlentherapie-Zweigpraxis vom MVZ Passau

Deggendorf, 94469, Germany

Location

Praxis für Strahlentherapie Krankenhaus Dresden-Friedrichsstadt

Dresden, 01067, Germany

Location

Malteser MVZ Duisburg-Süd

Duisburg, 470530, Germany

Location

Universitätsklinikum Düsseldorf Klinik und Poliklinik für Strahlentherapie und Radioologische Onkologie

Düsseldorf, 40225, Germany

Location

Gemeinschaftspraxis für Strahlentherapie und Radioonkologie

Elmshorn, 25337, Germany

Location

MVZ Strahlentherapie Klinikum Esslingen GmbH

Esslingen am Neckar, 73730, Germany

Location

Klinikum Frankfurt (Oder)Klinikum für Strahlentherapie Radioonkologie

Frankfurt (Oder), 15236, Germany

Location

Klinik für Strahlentherapie und Onkologie

Frankfurt/M, 60590, Germany

Location

Strahlentherapie am Klinikum Fürth

Fürth, 90766, Germany

Location

Strahlentherapiezentrum- Escher-Lippe(STZELL) und die Katholischen Kliniken-Emscher

Gelsenkirchen, 45899, Germany

Location

Justus-Liebig Universität Gießen Strahlentherapie

Giessen, 35392, Germany

Location

Praxis für Strahlentherapie Goch

Goch, 47574, Germany

Location

Brustzentrum ALB FILS Kliniken GMBH

Göppingen, 73035, Germany

Location

Ambulanzzentrum des UKE GmbH Bereich der Strahlentherapie

Hamburg, 20246, Germany

Location

Radiologische Ambulanz Fachärzte für Radiologie,Nuklearmedizin und Strahlentherapie

Hamburg, 22307, Germany

Location

Strahlenzentrum Hamburg

Hamburg, 22419, Germany

Location

GSR Hameln

Hamelin, 31785, Germany

Location

Gemeinschaftspraxis für Strahlentherapie und Radioonkologie / Hannover/Hildesheim/Hameln

Hanover, 30161, Germany

Location

GSR Hannover Siloa

Hanover, 30449, Germany

Location

Dr.med Jürgen Heide Facharzt für Strahlentherapie

Harburg, 21075, Germany

Location

Gemeinschaftspraxis für Strahlentherapie und Radioonkologie(GSR)

Hildesheim, 31134, Germany

Location

Gemeinschaftspraxis für Strahlentherapie Hildesheim/Goslar

Hildesheim, 31135, Germany

Location

Gemeinschaftspraxis für Strahlentherapie/Hildesheim/Goslar

Hildesheim, 31135, Germany

Location

Strahlentherapie Hof

Hof, 95032, Germany

Location

MVZ St. Vincent-Kliniken gAG

Karlsruhe, 76135, Germany

Location

Praxis für Strahlentherapie am Universitätsklinikum Schleswig-Holstein

Kiel, 24105, Germany

Location

Universitätsklinikum Schleswig-Holstein

Kiel, 24105, Germany

Location

Universitätsklinikum Leibzig

Leipzig, 04103, Germany

Location

Klinikum für Strahlentherapie - Klinikum Lippe

Lemgo, 32657, Germany

Location

Klinikum Ludwigsburg Klinik für Radioonkologie

Ludwigsburg, 71640, Germany

Location

Klinikum Lüneburg, Klinik für Strahlentherapie und Radioonkologie

Lüneburg, 21339, Germany

Location

MVZ Prof.Dr.Uhlenbrock und Partner Strahlentherapie Lünen

Lünen, 44534, Germany

Location

Klinik und Poliklinik für Radioonkologie und Strahlentherapie Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Mainz, 55131, Germany

Location

Praxis für Strahlentherapie Mannheim

Mannheim, 68309, Germany

Location

Universitätsklinikum Marburg Strahlentherapie und Radioonkologie

Marburg, 35033, Germany

Location

Brustzentrum Helios Klinikum

Meiningen, 98617, Germany

Location

MVZ Chariete Vivantes Gmbh Strahlentherapie

Mitte, 10249, Germany

Location

Kliniken Maria Hilf Gmbh Klinik für Strahlentherapie

Mönchengladbach, 41063, Germany

Location

Klinikum rechts der Isar

München, 81675, Germany

Location

Klinik für Strahlentherapie- Radioonkologie

Münster, 48149, Germany

Location

Praxis für Strahlentherapie und Radioonkologie am Clemenshospital

Münster, 48153, Germany

Location

Strahlentherapie Neckarsulm

Neckarsulm, 74172, Germany

Location

Dietrich Bonhoeffer Klinikum Neubrandenburg

Neubrandenburg, 17022, Germany

Location

Praxis für Strahlentherapie Im Städtischen Klinikum Neunkirchen

Neunkirchen, 66538, Germany

Location

Klinik für Strahlentherapie und Radioonkologie Pius-Hospital Oldenburg

Oldenburg, 26121, Germany

Location

Zentrum für Strahlentherapie Rheine-Osnabrück

Osnabrück, 49076, Germany

Location

MVZ Radio-LOG Schie in Altötting

Passau, 94032, Germany

Location

Visiorad - Bereich Strahlentherapie

Pinneberg, 25421, Germany

Location

Klinikum für Radioonkologie Klinikum Ernst von Bergmann

Potsdam, 14467, Germany

Location

Krankenhaus Barmherzige Brüder Regensburg Medizinisches Versorgungszentrum

Regensburg, 93049, Germany

Location

Überörtliche Gemeinschaftspraxis/Fachärzte für Strahlentherapie

Rheine, 48431, Germany

Location

Kreiskliniken Esslingen Paracelsus Krankenhaus Ruit

Ruit, 73760, Germany

Location

CaritasKlinikum Saarbrücken

Saarbrücken, 66113, Germany

Location

XCare Praxis für Strahlentherapie

Saarlouis, 66740, Germany

Location

MVZ Leopoldina Strahlentherapie

Schweinfurt, 97422, Germany

Location

MVZ Leopoldina

Schweinfurt, 97422, Germany

Location

Helios kliniken Schwerin GMBH

Schwerin, 19055, Germany

Location

Johanniter Zentren für medizinische Versorgung in der Altmark GMBH

Stendal, 39576, Germany

Location

Johanniter Zentrum für Medizinische Versorgung

Stendal, 39576, Germany

Location

MVZ Klinikum Straubing GMBH Strahlentherapie

Straubing, 94315, Germany

Location

MVZ-Uniklinik Tübingen gGmbH

Stuttgart, 70176, Germany

Location

Praxis für Strahlentherapie Trier Ehrang

Trier, 54293, Germany

Location

Universitätsklinikum Tübingen

Tübingen, 72076, Germany

Location

Klinik für Strahlentherapie und Radioonkologie Universitätsklinikum Ulm

Ulm, 89081, Germany

Location

Klinik für Strahlentherapie und Radioonkologie Schwarzwald-Baar -Klinikum

Villingen-Schwenningen, 78052, Germany

Location

Praxis für Strahlentherapie und Radioonkologie am Krankenhaus Weilheim

Weilheim, 82362, Germany

Location

Medizinisches Versorgungszentrum Wolfsburg GmbH

Wolfsberg, 38440, Germany

Location

Universitätsklinikum Würzburg Klinik und Poliklinik für Strahlentherapie

Würzburg, 97080, Germany

Location

Heinrich-Braun-Klinikum Zwickau

Zwickau, 08060, Germany

Location

Related Publications (1)

  • Krug D, Vonthein R, Schreiber A, Boicev AD, Zimmer J, Laubach R, Weidner N, Dinges S, Hipp M, Schneider R, Weinstrauch E, Martin T, Horner-Rieber J, Olbrich D, Illen A, Hessler N, Konig IR, Dellas K, Dunst J. Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial. Strahlenther Onkol. 2021 Sep;197(9):802-811. doi: 10.1007/s00066-020-01730-9. Epub 2020 Dec 15.

    PMID: 33320286BACKGROUND

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Jürgen Dunst, MD

    University Medical Center Schleswig-Holstein (UKSH)

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Juergen Dunst, Prof.

Study Record Dates

First Submitted

June 4, 2015

First Posted

June 18, 2015

Study Start

June 16, 2015

Primary Completion

January 8, 2019

Study Completion (Estimated)

March 31, 2028

Last Updated

March 21, 2024

Record last verified: 2024-03

Locations